Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a

Stefania Cortecchia, Giuseppe Galanti, Cecilia Sgadari, Silvano Costa, Margherita De Lillo, Licia Caprara, Giovanni Barillari, Paolo Monini, Roberto Nannini, Barbara Ensoli, Lauro Bucchi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: The p16Ink4a (p16) tumor-suppressor protein is a biomarker for activated expression of human papillomavirus oncogenes. However, data are insufficient to determine whether p16 overexpression predicts the risk for progression of low-grade cervical intraepithelial neoplasia (CIN). This study was aimed at evaluating the risk for progression to CIN2 or worse during a 3-year follow-up of an unselected series of 739 patients with CIN1 biopsy specimens tested for p16 expression. Methods: Positivity of p16 was defined as a diffuse overexpression in the basal/parabasal cell layers. Selection biases were ruled out using a control group of 523 patients with CIN1 biopsies not tested for p16 expression. Analysis was based on the ratio of progression rates. Results: In the first year of follow-up, the 216 patients (29%) with p16-positive CIN1 had a higher progression rate (12.3%) than did the 523 patients with p16-negative CIN1 (2.2%) (rate ratio, 5.5; 95% confidence interval [CI], 2.59-11.71). In the second and third years, differences were smaller (rate ratio, 1.32 and 1.14, respectively) and not significant. The patients with p16-positive CIN1 also had a lower risk for regression to normal in the first year of follow-up (rate ratio, 0.55; 95% confidence interval, 0.42-0.71) and nonsignificant changes in the second and third years (rate ratio, 0.81 and 0.84, respectively). Conclusions: The patients with p16-positive CIN1 had an increased risk for progression that was concentrated in the first year of follow-up. Immunostaining of p16 could have a role in short-term surveillance of patients with CIN1. Further research should focus on midterm/ long-term outcomes of p16-positive CIN1.

Original languageEnglish
Pages (from-to)1663-1669
Number of pages7
JournalInternational Journal of Gynecological Cancer
Volume23
Issue number9
DOIs
Publication statusPublished - 2013

Fingerprint

Cervical Intraepithelial Neoplasia
Cyclin-Dependent Kinase Inhibitor p16
Confidence Intervals
Tumor Suppressor Proteins
Biopsy
Selection Bias
Oncogenes
Biomarkers
Control Groups
Research

Keywords

  • Cervical intraepithelial neoplasia
  • P16
  • Progression
  • Regression

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a . / Cortecchia, Stefania; Galanti, Giuseppe; Sgadari, Cecilia; Costa, Silvano; De Lillo, Margherita; Caprara, Licia; Barillari, Giovanni; Monini, Paolo; Nannini, Roberto; Ensoli, Barbara; Bucchi, Lauro.

In: International Journal of Gynecological Cancer, Vol. 23, No. 9, 2013, p. 1663-1669.

Research output: Contribution to journalArticle

Cortecchia, S, Galanti, G, Sgadari, C, Costa, S, De Lillo, M, Caprara, L, Barillari, G, Monini, P, Nannini, R, Ensoli, B & Bucchi, L 2013, 'Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a ', International Journal of Gynecological Cancer, vol. 23, no. 9, pp. 1663-1669. https://doi.org/10.1097/IGC.0b013e3182a80b14
Cortecchia, Stefania ; Galanti, Giuseppe ; Sgadari, Cecilia ; Costa, Silvano ; De Lillo, Margherita ; Caprara, Licia ; Barillari, Giovanni ; Monini, Paolo ; Nannini, Roberto ; Ensoli, Barbara ; Bucchi, Lauro. / Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a . In: International Journal of Gynecological Cancer. 2013 ; Vol. 23, No. 9. pp. 1663-1669.
@article{64e3e5780c29490097eef77104165668,
title = "Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a",
abstract = "Objective: The p16Ink4a (p16) tumor-suppressor protein is a biomarker for activated expression of human papillomavirus oncogenes. However, data are insufficient to determine whether p16 overexpression predicts the risk for progression of low-grade cervical intraepithelial neoplasia (CIN). This study was aimed at evaluating the risk for progression to CIN2 or worse during a 3-year follow-up of an unselected series of 739 patients with CIN1 biopsy specimens tested for p16 expression. Methods: Positivity of p16 was defined as a diffuse overexpression in the basal/parabasal cell layers. Selection biases were ruled out using a control group of 523 patients with CIN1 biopsies not tested for p16 expression. Analysis was based on the ratio of progression rates. Results: In the first year of follow-up, the 216 patients (29{\%}) with p16-positive CIN1 had a higher progression rate (12.3{\%}) than did the 523 patients with p16-negative CIN1 (2.2{\%}) (rate ratio, 5.5; 95{\%} confidence interval [CI], 2.59-11.71). In the second and third years, differences were smaller (rate ratio, 1.32 and 1.14, respectively) and not significant. The patients with p16-positive CIN1 also had a lower risk for regression to normal in the first year of follow-up (rate ratio, 0.55; 95{\%} confidence interval, 0.42-0.71) and nonsignificant changes in the second and third years (rate ratio, 0.81 and 0.84, respectively). Conclusions: The patients with p16-positive CIN1 had an increased risk for progression that was concentrated in the first year of follow-up. Immunostaining of p16 could have a role in short-term surveillance of patients with CIN1. Further research should focus on midterm/ long-term outcomes of p16-positive CIN1.",
keywords = "Cervical intraepithelial neoplasia, P16, Progression, Regression",
author = "Stefania Cortecchia and Giuseppe Galanti and Cecilia Sgadari and Silvano Costa and {De Lillo}, Margherita and Licia Caprara and Giovanni Barillari and Paolo Monini and Roberto Nannini and Barbara Ensoli and Lauro Bucchi",
year = "2013",
doi = "10.1097/IGC.0b013e3182a80b14",
language = "English",
volume = "23",
pages = "1663--1669",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a

AU - Cortecchia, Stefania

AU - Galanti, Giuseppe

AU - Sgadari, Cecilia

AU - Costa, Silvano

AU - De Lillo, Margherita

AU - Caprara, Licia

AU - Barillari, Giovanni

AU - Monini, Paolo

AU - Nannini, Roberto

AU - Ensoli, Barbara

AU - Bucchi, Lauro

PY - 2013

Y1 - 2013

N2 - Objective: The p16Ink4a (p16) tumor-suppressor protein is a biomarker for activated expression of human papillomavirus oncogenes. However, data are insufficient to determine whether p16 overexpression predicts the risk for progression of low-grade cervical intraepithelial neoplasia (CIN). This study was aimed at evaluating the risk for progression to CIN2 or worse during a 3-year follow-up of an unselected series of 739 patients with CIN1 biopsy specimens tested for p16 expression. Methods: Positivity of p16 was defined as a diffuse overexpression in the basal/parabasal cell layers. Selection biases were ruled out using a control group of 523 patients with CIN1 biopsies not tested for p16 expression. Analysis was based on the ratio of progression rates. Results: In the first year of follow-up, the 216 patients (29%) with p16-positive CIN1 had a higher progression rate (12.3%) than did the 523 patients with p16-negative CIN1 (2.2%) (rate ratio, 5.5; 95% confidence interval [CI], 2.59-11.71). In the second and third years, differences were smaller (rate ratio, 1.32 and 1.14, respectively) and not significant. The patients with p16-positive CIN1 also had a lower risk for regression to normal in the first year of follow-up (rate ratio, 0.55; 95% confidence interval, 0.42-0.71) and nonsignificant changes in the second and third years (rate ratio, 0.81 and 0.84, respectively). Conclusions: The patients with p16-positive CIN1 had an increased risk for progression that was concentrated in the first year of follow-up. Immunostaining of p16 could have a role in short-term surveillance of patients with CIN1. Further research should focus on midterm/ long-term outcomes of p16-positive CIN1.

AB - Objective: The p16Ink4a (p16) tumor-suppressor protein is a biomarker for activated expression of human papillomavirus oncogenes. However, data are insufficient to determine whether p16 overexpression predicts the risk for progression of low-grade cervical intraepithelial neoplasia (CIN). This study was aimed at evaluating the risk for progression to CIN2 or worse during a 3-year follow-up of an unselected series of 739 patients with CIN1 biopsy specimens tested for p16 expression. Methods: Positivity of p16 was defined as a diffuse overexpression in the basal/parabasal cell layers. Selection biases were ruled out using a control group of 523 patients with CIN1 biopsies not tested for p16 expression. Analysis was based on the ratio of progression rates. Results: In the first year of follow-up, the 216 patients (29%) with p16-positive CIN1 had a higher progression rate (12.3%) than did the 523 patients with p16-negative CIN1 (2.2%) (rate ratio, 5.5; 95% confidence interval [CI], 2.59-11.71). In the second and third years, differences were smaller (rate ratio, 1.32 and 1.14, respectively) and not significant. The patients with p16-positive CIN1 also had a lower risk for regression to normal in the first year of follow-up (rate ratio, 0.55; 95% confidence interval, 0.42-0.71) and nonsignificant changes in the second and third years (rate ratio, 0.81 and 0.84, respectively). Conclusions: The patients with p16-positive CIN1 had an increased risk for progression that was concentrated in the first year of follow-up. Immunostaining of p16 could have a role in short-term surveillance of patients with CIN1. Further research should focus on midterm/ long-term outcomes of p16-positive CIN1.

KW - Cervical intraepithelial neoplasia

KW - P16

KW - Progression

KW - Regression

UR - http://www.scopus.com/inward/record.url?scp=84888379732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888379732&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e3182a80b14

DO - 10.1097/IGC.0b013e3182a80b14

M3 - Article

C2 - 24172101

AN - SCOPUS:84888379732

VL - 23

SP - 1663

EP - 1669

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -